Skip to content
Back to meeting Original
Urs Weber MD· @UrsWeberMD · X·· 1 day agoScore70
Body

SAFFRON provides further evidence for 2 key concepts:
1. Continue osimertinib post-progression.
2. Target MET overexpression.
My main concern with this particular approach is patient selection. How many patients have c-MET IHC 3+ >90%?
@EGFRResisters @myESMO #ESMO26

24 views · 0 likes · 0 reposts · 0 replies

引用@
Presented at #ESMO26: In patients with 𝘌𝘎𝘍𝘙-mutated and MET-altered non–small-cell lung cancer that had progressed during osimertinib therapy, osimertinib plus savolitinib (a MET tyrosine kinase inhibitor) led to longer survival than platinum–pemetrexed. Full phase 3 SAFFRON trial results: https://nej.md/4hXdueb @myESMO
在 X 查看被引用的帖子

Source: Urs Weber MD · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.